Hook & thesis
Hims & Hers has traded like a high-growth consumer tech name that got derailed by an earnings miss and short-term execution questions. That pain is real - the stock dropped double digits on the Q1 report - but the datapoints that matter for the next few quarters now point toward tangible revenue leverage: the Novo Nordisk settlement that allows reselling branded GLP-1s, rapid fulfillment (125,000 Wegovy shipments reported), and a raised full-year revenue guide to $2.8-3.0 billion. Those are operational wins you can build a trade around.
My take: this is a tactical long. Near-term headline risk will persist, but the combination of expanding pharmacy integration, strong unit economics in weight-loss fulfillment and an oversized addressable market gives a clear upside vector. Enter at $25.00, protect capital with a $20.00 hard stop, and target $38.00 over a mid-term period (45 trading days) where the market should re-rate execution into a higher multiple.
What the company does and why the market should care
Hims & Hers operates a telehealth-first consumer healthcare platform connecting users to clinicians and delivering medications and care for dermatology, sexual health, mental health, primary care and increasingly weight loss. Its transition from compounding GLP-1s to reselling brand-name products from major manufacturers is a clear strategic inflection: it converts a regulatory and margin risk into distribution scale and reliable supply.
Why this matters: GLP-1 medications are a structural demand driver for both prescription volume and recurring subscription-like behavior on a telehealth platform. Hims & Hers is positioning itself as a supply anchor and low-friction distribution channel for these drugs while also protecting other high-margin categories (e.g., hair, sexual health) through pharmacy integrations and inventory focus. If the company can capture a repeatable share of the weight-loss medication flow, revenue and gross margin expansion follow.
Key data points to anchor the argument
- Market capitalization sits at roughly $5.71 billion.
- The company raised full-year revenue guidance to $2.8-3.0 billion for FY2026 and projects $6.5 billion in sales by 2030.
- Q1 headlines were mixed: reported EPS missed expectations (reported loss of $0.40 vs. an expected small profit in consensus commentary) and revenue of $608 million fell short of the $616-619 million range analysts had modeled.
- Operational momentum: the Novo Nordisk channel fulfilled over 125,000 Wegovy shipments in the early pull-through period, showing early supply and logistics capability.
- Liquidity and attention: two-week average volume is ~22.5 million shares and 30-day average volume is ~34.6 million, so moves get priced quickly.
Technical and market structure context
Shares are trading at $25.03, below the 10-day and 20-day simple moving averages ($26.95 and $27.77) but above the 50-day SMA ($23.66), which creates a classic “short-term weakness into longer-term support” setup. RSI sits near 47 (neutral). Momentum indicators (MACD histogram negative) suggest short-term bearish pressure, but the stock is not deeply oversold and support in the low-$20s has held earlier this year (52-week low $13.74; 52-week high $70.43).
Short interest has been meaningful but declining: settlement on 04/30/2026 showed ~63.16 million shares short with days-to-cover around 1.48, and recent short volume on 05/12/2026 was ~14.13 million of total 25.48 million traded - a sign of ongoing two-way action where both sellers and short-sellers are active. That creates volatility but also potential squeeze mechanics on positive news flow.
Valuation framing
At a market cap of $5.71 billion and management's FY2026 revenue guide midpoint at $2.9 billion, the shares trade for roughly 2.0x forward revenue. That's a pragmatic multiple for a consumer healthcare platform with durable recurring revenue if the company can deliver on GLP-1 distribution and modest margin expansion. The trailing price-earnings ratio reads ~55.8, reflecting the combination of high-growth expectations and recent earnings volatility. Viewed through a revenue multiple lens, there is a path to multiple expansion if guidance proves conservative and subscriber metrics accelerate.
Comparative multiples across direct-to-consumer healthcare and pharmacy integrators vary, but the core logic is simple: if Hims & Hers converts GLP-1 fulfillment into an ongoing revenue stream that combines high-repeat customers and incremental pharmacy sales across other categories, the current ~2x revenue traded into 2.5-3x would justify a mid-teens to low-20s percentage upside even without large multiple expansions. The $38 target assumes such an execution shift and partial re-rating toward that range over the trade horizon.
Catalysts to watch (what could re-rate the stock)
- Execution on GLP-1 distribution: sustained weekly/monthly shipment cadence and margin disclosure related to reselling brand GLP-1s.
- Subscriber growth metrics: new and active subscribers trending above management's stated targets (subscriber guidance flagged as a key metric heading into the print).
- Pharmacy and supply partnerships: new integrations or exclusivity agreements that secure inventory in constrained categories (e.g., hormone therapy patches) and expand fulfillment capacity.
- Quarterly guidance or incremental full-year guide upside beyond the current $2.8-3.0B band.
- Macro catalysts: retail pharmacy entrants (Amazon, others) or pricing changes that make Hims & Hers’ competitive pricing advantage clearer to investors.
Trade plan - actionable specifics
Trade direction: Long
Entry price: $25.00
Stop loss: $20.00 (hard stop)
Target price: $38.00
Horizon: mid term (45 trading days). I expect this to be a mid-term trade because the market needs several weeks to reprice execution improvements and for GLP-1 volume to show up consistently in reported metrics or weekly shipment commentary. If the company posts another operational slip or guidance is cut, the plan is to exit at the stop and reassess.
Rationale: The entry sits near current trading levels and just above a technical cluster near the 50-day SMA. The $20 stop limits downside to ~20% from entry and puts you below a level of earlier support and where selling pressure historically intensified. The $38 target assumes the market re-rates the company closer to ~3x forward revenue on proof that GLP-1 distribution is sticky and accretive, combined with partial multiple expansion as growth stabilizes.
Position sizing guidance
This trade is best sized as a tactical swing allocation - consider limiting exposure to a single-digit percentage of a diversified equities sleeve given earnings volatility and the presence of large short interest. Scale into the entry if volume and price action confirm buyers around $24.50-$25.50.
Risks and counterarguments
- Earnings and execution risk: Q1 showed a meaningful EPS miss and a revenue miss. If misses continue, investor patience will erode and multiples could compress further.
- Margin pressure from reselling branded products: moving to branded GLP-1 reselling could compress gross margins versus compounded product economics, at least until scale and pricing negotiate out.
- Competitive threats: large incumbents (national pharmacies, Amazon) entering same-day or integrated pharmacy services could undercut pricing or take share on convenience.
- Regulatory and supply chain risk: supply disruptions for GLP-1s or new regulatory constraints on telehealth prescribing could blunt the company's strategic advantages.
- Sentiment risk and short squeeze volatility: high short interest and large daily short volumes create two-way risk. Positive news can spike the stock; negative headlines can accelerate downside quickly.
Counterargument: A reasonable bear case is that the GLP-1 pivot merely swaps one set of risks for another: regulatory and margin risk for supply reliability and inventory risk. If branded drug economics prove worse than management expects and competition scales quicker, revenue growth could be less profitable and the stock could settle at a lower multiple for longer. That outcome would invalidate the trade thesis and argue for staying on the sidelines.
What would change my mind
I would reduce conviction or flip to neutral/short if we saw either: (a) another revenue or EPS miss with guidance trimmed below the current $2.8-3.0 billion band, or (b) public evidence of endemic margin erosion tied to the branded GLP-1 resale model. Conversely, sustained weekly shipment numbers above the initial 125,000 clip and subscriber growth accelerating beyond management targets would increase conviction and push my target higher.
Conclusion
Hims & Hers is a classic execution vs. expectation story. The Q1 miss is not trivial, but the strategic pivot to reselling brand GLP-1s via the Novo Nordisk arrangement and a raised revenue guide convert the narrative into something measurable. That makes a disciplined, mid-term long trade actionable: an entry at $25.00, a $20.00 stop to protect capital, and a $38.00 target that prices in both growth and partial multiple recovery. Take a staged approach, watch shipment cadence and subscriber trends, and use the stop if the thesis unravels.
Key dates to monitor
- Recent Q1 headlines and commentary on 05/12/2026 - watch follow-up investor calls and weekly shipment disclosures.
- Upcoming quarterly update cadence and any mid-quarter operational reads on pharmacy integrations or supply announcements.
Bottom line: The headline miss created an entry. The GLP-1 deal and raised guidance create the path. Trade it with discipline.